Streetbeat News

Revenues

LYRA

A new post-hoc analysis of pooled Phase 3 data reveals that INPEFA (Sotagliflozin) significantly reduces the risk of heart failure events in patients with preserved ejection fraction. This finding could have substantial implications for the treatment of heart failure, potentially positioning INPEFA as a leading therapeutic option in this patient population. The analysis, which draws on data from several Phase 3 trials, underscores the drug's efficacy in a condition that has historically been challenging to manage.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:04 am

CCLD

CareCloud has reiterated its FY24 revenue guidance, projecting $118M–$120M, slightly above the $117.72M estimate. The company also expects adjusted EBITDA to be between $21M and $23M.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:03 am

OPTN

OptiNose reported Q1 EPS of $(0.12), missing the $(0.11) estimate, but its sales of $14.88M exceeded the $12.94M forecast. This represents a 29.41% increase in losses and a 25.61% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:03 am

HYFM

Hydrofarm Holdings Group (HYFM) has reiterated its FY24 outlook, expecting net sales to decrease in the low to teens percentage terms. Despite the sales decline, the company anticipates positive adjusted EBITDA and free cash flow. Capital expenditures are projected to be around $4M-$5M.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:03 am

HYFM

Hydrofarm Holdings Group (HYFM) reported Q1 2024 GAAP EPS of $(0.28) with sales of $54.172M, surpassing the $50.350M estimate. This represents a 7.59% beat on sales estimates but a 12.88% decrease from the previous year's sales of $62.178M.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:01 am

AUMN

Golden Minerals (AMEX:AUMN) reported a Q1 EPS of $(0.32), improving from $(0.50) YoY. However, sales decreased to $1.20M from $4.20M YoY, marking a 71.43% decline.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:49 am

IGT

Intl Game Tech (IGT) projects Q2 revenue of approximately $1.05 billion, slightly below the estimated $1.09 billion. The company has also upgraded its full-year 2024 outlook, expecting revenues of around $4.4 billion, with operating income margins of about 21% (24% excluding separation and divestiture costs), cash from operations of at least $1.0 billion, and capital expenditures of approximately $500 million.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:45 am

AB

CG

MAIN

OWL

Carlyle Group (NASDAQ:CG) reported Q1 earnings, beating estimates with an EPS of $1.01 against the expected $0.94 and revenue up $268.80 million YOY. The company's past performance shows consistent EPS growth. Competitors Blue Owl Cap, Main Street Capital, and AllianceBernstein also exceeded EPS expectations, with respective increases of 6.25%, 8.82%, and 2.82%. Revenue performance across these companies varied, with AllianceBernstein leading with a 22.29% surprise.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 10:16 am

HBM

Hudbay Minerals projects its FY26 copper production to be between 134,000 and 168,000 tonnes, and gold production to range from 209,000 to 254,000 ounces.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:11 am

AUPH

A recent analysis presented at the National Kidney Foundation's Spring Clinical Meeting 2024 has shown that LUPKYNIS is a cost-effective treatment for Lupus Nephritis. This finding could have significant implications for its manufacturer, Aurinia Pharmaceuticals Inc. (AUPH), in terms of market positioning and potential sales growth.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:09 am